Short- and long-term post–renal transplant follow-up at Charles Nicolle Hospital

Abstract

years, 56.5%; 31 to #45 years, 33.5%; and .45 years, 4%. Primary renal disease was chronic glomerulonephritis in 85 cases (42.5%), chronic pyelonephritis in 43 (21.5%), nephroangiosclerosis in 17 (8.5%), hereditary nephropathy in 11 (5.5%), and unknown in 44 (22%). Initial renal replacement therapy (RRT) was hemodialysis (HD) in 155 cases (77.5%), continuous ambulatory peritoneal dialysis (CAPD) in 24 (12%) and the two techniques combined in 21 (10.5%). For LRD, only first-degree relatives who gave their informed consent were accepted. All patients received ABO compatible and cross-match negative kidneys. At least 3 units of blood transfusions were given to 161 patients (80.5%) and cytotoxic antibodies were screened. All patients received a combination of prednisolone: 2 mg/kg/d on day 0, tapered to 0.2 mg/kg/d on day 90 and azathioprine at 125 mg/d. Antilymphocyte globulin (ALG) or antithymocyte globulin (ATG) was used as prophylactic treatment of graft rejection in 98 cases (48%) during the first 15 days. Cyclosporine was administered in 112 patients (56%) twice daily orally at 5 mg/d beginning on day 3 to 15 days in LRD transplants with one identical haplotype and after corticoresistant acute rejection episodes. The dosages were adjusted to clinical state and cyclosporine blood level (radioimmunoassay). Acute rejection episodes were treated with a combination of pulses of methylprednisolone and ALG/ATG in 75 cases. OKT3 was introduced in six cases when ALG/ATG failed to reverse the rejection. Mycophenolate mofetil was used in 11 cases with cyclosporine nephrotoxicity. The results were expressed as mean 6 standard deviation (SD). Comparisons were made with chi squared test for categorical variables and PLSD Fisher’ test for continuous variables. The survival rates were computed using the actuarial method. P , .05 was considered statistically significant. RESULTS The waiting time on dialysis was 28 6 22 months (1 to 119 months). For LRD, the donors were 96 (52.7%) siblings, 84 (46.2%) parents, and 2 children. HLA matching was 0 mismatches (MM) in 48 cases (26.4%) and 3 MM in 134 (73.6%). Their mean age was 38.6 6 13.4 (16 to 65) years. For CAD, HLA matching was 1 to 6 MM. The cytotoxic antibodies were positive in 27% of cases. Acute tubular necrosis (ATN) occurred in 26 cases (14.3%) of LRD and in 3 (16.7%) CAD. All those patients were hemodialyzed requiring 1 to 10 sessions, but all recovered. The difference between the two groups was not statistically significant (P 5 .07). The mean time of warm ischemia was 44 6 13 minutes for patients who have expressed ATN and 41.9 6 10.9 for those without ATN. The mean time of cold ischemia for CAD was 26.8 6 6 hours. Acute rejection was encountered in 16 (33.3%) cases of LRD with 0 MM, 80 (59.7%) cases of LRD with 3 MM, and 14 (77.8%) cases in the CAD group. The differences between the three groups were statistically significant (P , .0009). Complications Infectious complications were very common (86% of cases). Viral infections occurred in 40% of cases, mostly CMV (21%) and herpes (14%). No HIV infection was seen. Bacterial infections occurred in 60% of cases, mostly urinary tract infections (49%), septicemia (11.5%), and bronchopulmonary infections (5%). Six patients had scabies. Urologic complications occurred in 31 cases: 14 (7%) urinary leaks, 6 (3%) urinary stenosis, 2 ureteral compressions, 4 lymphoceles, 3 urinary lithiasis, and 2 urinary tuberculosis. Vascular complications were seen in eight cases: two arterial thrombosis, two venous thrombosis, three arteriovenous fistulae, and one perirenal hematoma. We noted recurrence of focal segmental glomerulosclerosis in six cases and glomerulonephritis de novo in two cases.